Sanam Loghavi
Overview
Explore the profile of Sanam Loghavi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
253
Citations
3694
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fiskus W, Mill C, Piel J, Collins M, Hentemann M, Cuglievan B, et al.
Blood Cancer J
. 2025 Mar;
15(1):40.
PMID: 40089460
Although treatment with standard frontline therapies, including a FLT3 inhibitor (FLT3i) reduces AML burden and achieves clinical remissions, most patients with AML with FLT3 mutation relapse due to therapy-resistant stem/progenitor...
2.
3.
Gisriel S, Aakash F, Bennett J, Hasserjian R, Loghavi S, DeZern A, et al.
Arch Pathol Lab Med
. 2025 Mar;
PMID: 40059041
Context.—: Standardized bone marrow reporting specifically for myelodysplastic syndromes/neoplasms (MDS) is currently lacking in the literature and much needed in practice. Objective.—: To propose a standardized approach to MDS evaluation...
4.
DiNardo C, Jen W, Takahashi K, Kadia T, Loghavi S, Daver N, et al.
Leukemia
. 2025 Feb;
PMID: 40000842
Intensive chemotherapy remains the standard for newly diagnosed (ND) acute myeloid leukemia (AML); however, relapse risk remains high. Additionally, most patients with relapsed/refractory (RR) AML have poor outcomes. We report...
5.
6.
7.
Senapati J, Loghavi S, Marvin-Peek J, Garcia-Manero G, Kadia T, Borthakur G, et al.
Am J Hematol
. 2025 Feb;
PMID: 39921561
Ontogeny of acute myeloid leukemia (AML) provides prognostic information, however closer interrogation with respect to AML characteristics, genomics, and various treatments are warranted. We defined untreated clinical secondary (CS) AML...
8.
Wei Q, Hu S, Loghavi S, Toruner G, Ravandi-Kashani F, Tang Z, et al.
Am J Hematol
. 2025 Jan;
100(3):417-426.
PMID: 39871121
Chromoanagenesis (CAG) encompasses a spectrum of catastrophic genomic events, including chromothripsis, chromoanasynthesis, and chromoplexy. We studied CAG in 410 patients with a diagnosis of acute myeloid leukemia (AML), 292 newly...
9.
Loghavi S, Medeiros L
Hum Pathol
. 2025 Jan;
156:105720.
PMID: 39862928
We provide an overview of recent advances in the diagnosis and classification of intestinal T- and NK-cell lymphomas and lymphoproliferative disorders that primarily involve the gastrointestinal (GI) tract. It should...
10.
Wei Q, Hu S, Xu J, Loghavi S, Daver N, Toruner G, et al.
Cancers (Basel)
. 2025 Jan;
16(24.
PMID: 39766092
partial tandem duplication (PTD) involves intragenic duplications and has been associated with poorer prognosis. In this study, we evaluated PTD in 1277 patients with hematological malignancies using optical genome mapping...